Form 8-K Axsome Therapeutics, For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities
February 18, 2025 1:13 PM ESTTruist Securities analyst Joon Lee raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "4Q24. No surprises to results preannounced in January. More importantly, Ph3 study of solriamfetol in... More
